Oncogenic mutations at codons Gly 12, 13, and Gln 61 of KRAS occur in ~86% of KRAS-mediated human cancers, including pancreatic (90%), colon (40%), and non-small cell lung cancer (20%) [52]. The gene discussed is KRAS; the disease is cancer.